AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring

Recruitingn/aAges 18 Years - 80 YearsAllXiangya Hospital of Central South University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Aged 18-80 years, no gender restrictions. 2. Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis. 3. On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score โ‰ค 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to โ‰ค 5 (total GCS score โ‰ค 8). 4. Able to undergo continuous multimodal monitoring, with an expected ICU stay of โ‰ฅ72 hours. 5. Informed consent signed by the family or legal representative. Exclusion Criteria: 1. Confirmed brain death on admission or imaging showing irreversible brain herniation. 2. Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment. 3. Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus). 4. Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems). 5. Predicted survival time \<24 hours after admission, or family members choose to withdraw treatment. 6. Refusal to participate in the study by the patient or their legal representative.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
XiangyaHospital of Central South University
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy